Skip to main content
$6.56 -0.26 (-3.81%) At close · Jul 29
Market Cap
$55.70M
Shares
8.49M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$30.25M -46.5%
FY2025 Revenue FY2020–FY2025
Net Income
-$374.05M -413.8%
FY2025 Net Income FY2020–FY2025
Gross Margin
415.83% +120pp
FY2025 Gross Margin FY2024–FY2025
Operating Margin
-1143.71% -996.3pp
FY2025 Operating Margin FY2020–FY2025
Diluted EPS
-$22.71 -353.2%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
$3.82M -80.3%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
$33.86M $30.25M $56.59M $46.74M $38.03M $31.32M $23.56M
$13.66M $10.6M $16.69M $15.68M $10.8M $3.63M $2.15M
$125.8M $167.4M
415.83% 295.81%
$21.46M $20.71M $9.64M $12.75M $9.05M $9.2M $9.96M
$269.86M $266.88M $119.02M $119.64M $64.9M $50.58M $42.97M
$5.45M $4.36M $4.03M $4.11M $3.92M $3.74M $3.74M
$4.62M $4.05M $4.15M $3.96M $3.78M $3.78M
-$350.28M -$346.01M -$83.4M -$105.43M -$50.63M -$35.84M -$35.26M
-1143.71% -147.37% -225.55% -133.13% -114.44% -149.65%
-$341.38M -$79.35M -$101.29M -$46.67M -$32.06M -$31.48M
$12.76M $11.46M $1.96M $1.07M $9.6M $11.76M $13.12M
-$43.32M -$28.02M $10.59M -$8.89M $27.27M -$52.58M -$12.31M
-$393.6M -$374.03M -$72.81M -$114.32M -$23.36M -$88.42M -$47.57M
$26K -$1000 $13K $4000 $5000 -$53K
-$393.62M -$374.05M -$72.81M -$114.33M -$23.36M -$88.42M -$47.52M
-1236.42% -128.66% -244.59% -61.43% -282.35% -201.69%
$11.8M
-$419.68M -$402.49M -$72.81M -$166.98M -$23.36M -$88.42M
-$388.79M -$370.85M -$66.49M -$114.33M
USD/shares -$22.71 -$4.51 -$27.90 -$3.70 -$14.60 -$7.85
USD/shares -$22.71 -$5.01 -$27.90 -$3.70 -$14.60 -$7.85
shares 17.72K 16.16K 5.98M 6.16M 6.1M 6097.7985
shares 17.72K 16.29K 5.98M 6.16M 6.1M 6097.7985
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $17.3M in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Drug Manufacturers - General median 4.47×
EV/EBIT
P/E (TTM)
Drug Manufacturers - General median 24.74×

Valuation over time computed as of each quarter's filing date

Key facts CIK 1820190 CUSIP 80880W205 13F (30d) 24 filings 24 filers Visit website Investor relations